MedTrace Logo

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

NCT00543361 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 382

Last updated 2015-06-12

No results posted yet for this study

Summary

The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

MK0767

Duration of Treatment: 52 Weeks

DRUG

Comparator: placebo (unspecified)

Duration of Treatment: 52 Weeks

DRUG

Comparator: metformin

Duration of Treatment: 52 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2003-12-31
Completion
2003-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00543361 on ClinicalTrials.gov